MYC and lung adenocarcinoma: CRISPR/Cas9‐mediated deletion (1,555–1,727 bp) of a part of the super‐enhancer region of MYC, which is bound by the transcriptional co‐activator EP300, reduced the expression of MYC by ~30% in human H2009 lung adenocarcinoma cells (Zhang et al, 2016).